Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis
Pooled result · Low disease activity, patients with average baseline expected probabilityResult — go to the resultOdds ratio 6.31 95% CrI 2.22–15.25Authors' conclusion
In this individual participant data meta-analysis, adding certolizumab was associated with more effectiveness for rheumatoid arthritis in general. However, the benefit was uncertain for patients with low or high baseline expected probability, for whom other evaluations were necessary.
Study context
- Population
- Patients with moderate to high activity RA in RCTs (mean [SD] age 52.7 [12.3] years; 79.1% female)
- Participants
- 3,790 patients5 RCTs
- Comparison
- Certolizumab plus conventional antirheumatic drugs vs placebo plus conventional drugs
- Outcome
- Low disease activity or remission (DAS28, CDAI or SDAI)
- Follow-up
- 3 months
Methodological details2-stage model, penalized logistic regression (stage 1), bayesian IPD meta-regression (stage 2)
- 2-stage model
- Penalized logistic regression (stage 1)
- Bayesian IPD meta-regression (stage 2)
Pooled result
As reported in the abstract
Low disease activity, patients with average baseline expected probability
Odds ratio
6.31
95% CrI 2.22–15.25
Certolizumabvs Placebo
OR 6.31 (95% CrI 2.22–15.25)
Further pooled results
- Estimated risk difference smaller than 10% for patients with either low or high baseline expected probability
Original publication
Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis. JAMA Netw Open. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →